Extracorporeal Liver Support: An Updated Review of Mechanisms and Current Literature

Abstract

Introduction Acute liver failure is a cause of major mortality in the United States. Although the liver possesses regenerative capabilities, liver transplantation is the mainstay of treating acute liver failure. This modality is associated with many financial and logistic challenges. In this regard, Extracorporeal Liver Support (ECLS) might help in reducing mortality as well as bridge a patient to liver transplant. In some cases, the sequelae of liver failure such as hepatic encephalopathy and multi-organ failure can be postponed long enough for the native liver to self-recover function. With this rationale, we sought to describe the mechanism of various ECLS modalities, provide an overview of the current evidence regarding its use and to highlight future advancements that could overcome hindrances in its use. Methods A scoping review was performed using PubMed and other databases from 1990 to 2020 with the keywords: ‘extracorporeal liver support’, ‘acute liver failure’, ‘acute on chronic liver failure’, ‘albumin dialysis’, ‘artificial’ and ‘bioartificial’. Results and conclusions ECLS has shown significant improvements in bilirubin and urea levels. Various forms of ECLS might also reduce mortality due to liver failure. However, many complications, such as hypotension, anemia, bleeding issues, sepsis, can be anticipated. There are a few barriers to mainstream use of ECLS, such as specific design requirements and high cost that reduce the overall utility of this modality in a small group of liver transplant candidates. Furthermore, a multidisciplinary team approach is required to supervise ECLS, a luxury only available at major academic hospitals. Some advancements for overcoming these barriers include investigation of new scaffolding systems. In order to expand the usage of ECLS, clinical trials focusing on a comparison of different modalities of ECLS with renal replacement therapy in patients with liver failure should be promoted.

Roquin-1 resolves sepsis-associated acute liver injury by regulating inflammatory profiles via miRNA cargo in extracellular vesicles

“… 36 In the event of liver malfunction, organ replacement is difficult and laborious, and most bridges repair the liver within brief time intervals. 37 Multiple variables, including genetic predisposition, gender, current immunological condition, pre-existing damage, and the invading pathogen, influence the liver’s response to infection. 38 This intricacy may be one reason why no particular therapeutic therapy for septic liver failure has been identified.…”

Recent Advances in Liver Tissue Engineering as an Alternative and Complementary Approach for Liver Transplantation

“…A fully functional liver is the ultimate aim of LTE, and functional liver tissue can be used for drug testing [2,18]. Moreover, LTE has the potential to develop an extracorporeal liver support (ECLS) system performing the essential functions of the liver to reduce mortality or to bridge a patient to a liver transplant [19]. With recent advances in the field of regenerative medicine, tissue engineering holds high potential to progress as an alternative or supplement to LT. A major advance in the LTE area was published by Chhabra and colleagues, reporting the development of a vascularized liver model to understand liver regeneration [20].…”

Blood Purification in Hepatic Dysfunction after Liver Transplant or Extensive Hepatectomy: Far from the Best-Case Scenarios

“…Impaired hepatic detoxification, protein synthesis and metabolism lead to the accumulation of water-soluble, albumin-bound toxins and inflammatory mediators, which play a crucial role in the development of cardiovascular and neurotoxic complications, even leading to multi-organ failure (MOF) [3]. Several extracorporeal liver support systems have been tested in patients with HD as a bridge to recovery or LT [4,5]. The most widely used device is the molecular adsorbent recirculating system (MARS), which is designed to remove albumin-bound 2 of 11 toxins.…”